News

  • 5 November 2012

    Creabilis SA, a European biotechnology company specialising in the development of treatments in dermatology, inflammation and pain today announces that it has been granted a prestigious Biomedical Catalyst funding award, of £1.42m. Creabilis is one of the first companies to receive this award that will be used to advance the development of its clinical stage topical kinase inhibitor, CT327.

  • 30 October 2012

    Sequana Medical is pleased to announce that it has received CE mark approval for use of its alfapump® system in patients with ascites caused by cancer (malignant ascites). The alfapump® system was first introduced to the European market last year for patients with refractory ascites caused by advanced liver disease. The system is fully implantable, and automatically and continually collects ascites from the abdominal cavity and moves it to the bladder, where it is excreted naturally from the body.

  • 22 October 2012

    Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it would present the latest REDUCE-HTN renal denervation clinical study data at this year’s Transcatheter Cardiovascular Therapeutics (TCT) meeting to be held Oct. 22-26 at the Miami Beach Convention Center in Miami.

  • 17 September 2012

    Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it has received approval from Australia’s Therapeutic Goods Administration (TGA) for its V2 Renal Denervation System™ for the treatment of hypertension. Renal denervation is a percutaneous, catheter-based therapy that uses RF energy to disrupt renal sympathetic nerves whose hyperactivity leads to uncontrolled high blood pressure.

  • 28 June 2012

    Proceeds To Advance Development and Commercialize Treatment for Root Canal Therapy

    Sonendo, Inc. (formerly known as Dentatek Corporation), a privately-held company developing disruptive technologies to transform endodontic therapy, announced today that it has agreed to terms for a $20 million equity financing of which $9.2 million has been invested in an initial closing.  The round was led by OrbiMed Advisors, LLC, with NeoMed Management joining existing investors, including Fjord Ventures Management.  The proceeds from the financing will be used to finalize technology development, fund clinical studies and commercialize Sonendo's first endotherapy system.  Vince Burgess of OrbiMed and Erik Amble of NeoMed have joined the company's board of directors.